The efficacy and tolerability of cinnarizine (75 mg, at bedtime) in migraine prophylaxis and the presence of possible predictive factors for therapeutic responsiveness were evaluated in an open-label pilot trial. Eighty consecutive outpatients suffering from migraine with or without aura participated in the study. After 12 weeks of therapy, 55 patients experienced a greater than 66% reduction in headache frequency and were considered responders. A significant reduction in the number of migraine days (mean reduction 58+/-8%) and in intake of medication to treat acute attacks (mean reduction 55+/-11%) was also observed. Cinnarizine was well tolerated, as documented by the low number of adverse effects. Failure to respond to previous prophylactic treatments was a negative predictive factor correlated with a poor prognosis. This study, even bearing in mind its limitations as an open-label trial, suggests that cinnarizine might be an effective prophylactic anti-migraine agent. The clinical characteristics of migraine patients do not help to predict response to treatment.
Cinnarizine in migraine prophylaxis: efficacy, tollerability and predictive factors for therapeutic responsiveness. An open-label pilot trial / Rossi, P; Fiermonte, Giancarlo; Pierelli, Francesco. - In: FUNCTIONAL NEUROLOGY. - ISSN 0393-5264. - STAMPA. - 18:3(2003), pp. 155-159.
Cinnarizine in migraine prophylaxis: efficacy, tollerability and predictive factors for therapeutic responsiveness. An open-label pilot trial.
FIERMONTE, Giancarlo;PIERELLI, Francesco
2003
Abstract
The efficacy and tolerability of cinnarizine (75 mg, at bedtime) in migraine prophylaxis and the presence of possible predictive factors for therapeutic responsiveness were evaluated in an open-label pilot trial. Eighty consecutive outpatients suffering from migraine with or without aura participated in the study. After 12 weeks of therapy, 55 patients experienced a greater than 66% reduction in headache frequency and were considered responders. A significant reduction in the number of migraine days (mean reduction 58+/-8%) and in intake of medication to treat acute attacks (mean reduction 55+/-11%) was also observed. Cinnarizine was well tolerated, as documented by the low number of adverse effects. Failure to respond to previous prophylactic treatments was a negative predictive factor correlated with a poor prognosis. This study, even bearing in mind its limitations as an open-label trial, suggests that cinnarizine might be an effective prophylactic anti-migraine agent. The clinical characteristics of migraine patients do not help to predict response to treatment.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.